The joint marketing and development effort between Siemens andultrafast CT developer Imatron has yet to translate into successfor the South San Francisco, CA-based company. Imatron last monthposted disappointing financial results for 1992 and
The joint marketing and development effort between Siemens andultrafast CT developer Imatron has yet to translate into successfor the South San Francisco, CA-based company. Imatron last monthposted disappointing financial results for 1992 and attributedthe numbers to lower scanner sales.
Imatron reported revenues of $14.3 million for 1992 (end-December),down $8.6 million from revenues of $22.9 million the year before.The company suffered a net loss of $6.5 million last year, comparedto a net income of $1 million in 1991.
Imatron and the German vendor signed a marketing and developmentagreement in March 1991 that included Imatron's ultrafast CT machine(SCAN 12/2/92). The unit was redesigned, given a spiral scanningmode and dubbed Evolution EBT, a name derived from the electronbeam tomography technology that enables faster scanning.
Faster scanning has not yet led to faster sales, however. Thecompanies sold fewer Evolution EBTs last year than expected, accordingto Imatron chairman Douglas P. Boyd.
"Imatron breaks even when we ship 14 scanners a year,and last year the number was around nine or 10," Boyd said.
A factor in the slow start is the change from Imatron's olderultrafast CT model, C-100, to the Siemens model, which Imatronrefers to as C-150. The C-150 marketing program started severalmonths late, Boyd said. Four C-150 scanners were shipped lastyear, he said.
Another problem was the sluggish equipment purchasing market,in which few buyers were willing to pay Evolution's $1.95 millionlist price.
Siemens remains pleased with Evolution's progress, accordingto Boyd, who predicts growth this year in overseas sales, particularlyin Asia. A drop in overseas sales last year hurt the company'srevenues, he said.
In order to promote the unique applications made possible byEvolution's speed, Imatron has opened a dedicated cardiac screeningclinic at the company's South San Francisco headquarters. HeartScanImaging serves as a showplace for Evolution's coronary arteryscanning, Boyd said.
The clinic screens patients considered to be at risk for coronaryartery disease but who do not have symptoms of atherosclerosis.
"We are looking for coronary calcification, which hasbeen identified to be 100% specific as a marker for atherosclerosis,"Boyd said.
Ultrafast CT screening should prove superior to electrocardiogramtreadmill tests, which are neither very specific nor very sensitive,according to Boyd.
"This is really the first time there has been an effectivescreening test for coronary artery disease," Boyd said. "We'reinterested in looking at the progression of the disease as well."
The tests are being offered to the public at $375 per scan.Imatron will hold an open house in May to familiarize area physicianswith the service.
BRIEFLY NOTED:
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.